Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

We are excited to launch GCTx to broaden the accessibility of cell therapy and advance our pipeline of potential best-in-class treatments in various therapeutic areas starting with gastrointestinal, ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

The global pharmaceutical drug delivery market is set to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029 ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...